LONG-TERM BEVACIZUMAB TREATMENT IN PATIENTS WITH METASTATIC COLORECTAL CANCER WHO ARE RECEIVING FOLFOX4 AND FOLFIRI CHEMOTHERAPY

被引：0
|
作者：
Davidenko, Irina [1 ]
Kazantseva, Margarita [2 ]
Potemin, Sergey [2 ]
Elizbaryan, Karina [2 ]
Mamaeva, Elena [2 ]
Burdik, Oksana [2 ]
机构：
[1] Krasnodar City Oncol Ctr, Krasnodar, Russia
[2] Krasnodar Oncol Ctr, Krasnodar, Russia
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：98 / 98
页数：1
相关论文
共 50 条
  • [31] Motesanib with or without panitumumab plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer
    Niall Tebbutt
    Dusan Kotasek
    Howard A. Burris
    Lee S. Schwartzberg
    Herbert Hurwitz
    Joe Stephenson
    Douglas J. Warner
    Lisa Chen
    Cheng-Pang Hsu
    David Goldstein
    Cancer Chemotherapy and Pharmacology, 2015, 75 : 993 - 1004
  • [32] Motesanib with or without panitumumab plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer
    Tebbutt, Niall
    Kotasek, Dusan
    Burris, Howard A.
    Schwartzberg, Lee S.
    Hurwitz, Herbert
    Stephenson, Joe
    Warner, Douglas J.
    Chen, Lisa
    Hsu, Cheng-Pang
    Goldstein, David
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 75 (05) : 993 - 1004
  • [33] FOLFOXIRI Plus Bevacizumab Versus FOLFOX/FOLFIRI Plus Bevacizumab for Metastatic Colorectal Cancer: An Updated Meta-Analysis
    Muhibullah, Fnu
    Shafique, Nouman
    Khakwani, Anum
    Qadeer, Abdul
    Bajwa, Shammas Farooq
    Ehsan, Amna
    Aiman, Wajeeha
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S175 - S176
  • [34] Stop and Go FOLFOX plus Bevacizumab Chemotherapy in the First-Line Treatment of Metastatic Colorectal Cancer
    Vaidyanathan, Gayatri
    Groman, Adrienne
    Wilding, Gregory
    Fakih, Marwan G.
    ONCOLOGY, 2010, 79 (1-2) : 67 - 71
  • [35] Therapy monitoring with FDG PET in patients with metastatic colorectal cancer receiving FOLFOX chemotherapy.
    Dimitrakopoulou-Strauss, A
    Strauss, L
    Rudi, J
    JOURNAL OF NUCLEAR MEDICINE, 2002, 43 (05) : 22P - 23P
  • [36] Oxaliplatin and infused fluorouracil plus leucovorin (FOLFOX4) as first line treatment in elderly patients with metastatic colorectal cancer patients
    Addamo, G.
    Coccorullo, Z.
    Venturino, A.
    Colloca, G.
    Ratti, R.
    Guarneri, D.
    Campora, E.
    ANNALS OF ONCOLOGY, 2006, 17 : XI45 - XI45
  • [37] Overweight is associated with better prognosis in metastatic colorectal cancer patients treated with bevacizumab plus FOLFOX chemotherapy
    Cybulska-Stopa, Bozena
    Lugowska, Iwona
    Wisniowski, Rafal
    Domagala-Haduch, Malgorzata
    Rajczykowski, Marcin
    Piejko, Karolina
    Bar-Letkiewicz, Ilona
    Suwinski, Rafal
    Regulski, Krzysztof
    Mackiewicz, Jacek
    WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2020, 24 (01): : 34 - 41
  • [38] Treatment Patterns and Clinical Outcomes in Patients With Metastatic Colorectal Cancer Initially Treated with FOLFOX-Bevacizumab or FOLFIRI-Bevacizumab: Results From ARIES, a Bevacizumab Observational Cohort Study
    Bendell, Johanna C.
    Beikaii-Saab, Tanios S.
    Cohn, Allen L.
    Hurwitz, Herbert I.
    Kozloff, Mark
    Tezcan, Haluk
    Roach, Nancy
    Mun, Yong
    Fish, Susan
    Flick, E. Dawn
    Dalal, Darshan
    Grothey, Axel
    ONCOLOGIST, 2012, 17 (12): : 1486 - 1495
  • [39] FDA drug approval summary: Bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer
    Cohen, Martin H.
    Gootenberg, Joe
    Keegan, Patricia
    Pazdur, Richard
    ONCOLOGIST, 2007, 12 (03): : 356 - 361
  • [40] PHARMACOECONOMIC ANALYSIS OF DIRECT MEDICAL COSTS OF METASTATIC COLORECTAL CANCER THERAPY WITH XELOX OR FOLFOX4 WITH OR WITHOUT BEVACIZUMAB AS THE FIRST-LINE TREATMENT
    Tikhomirova, A.
    Kulikov, A.
    Yagudina, R.
    VALUE IN HEALTH, 2010, 13 (07) : A267 - A267
12345